Oncology Phase 2 Deal Benchmarks — US Only (2026)
Median upfront of $129M with total deal values reaching $1.1B in US Only territory.
Median Upfront
$129M
Total Deal Value
$819M
Royalty Range
6.8%–15.2%
Territory Multiplier
0.55x
Understanding Oncology Deal Benchmarks at Phase 2
Phase 2 Oncology licensing deals in US Only territory command a median upfront payment of $129M, with values ranging from $72M at the low end to $182M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $532M to $1.1B, with a median of $819M. Royalty rates for oncology assets at this stage typically fall between 6.8% and 15.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $72M | $129M | $182M |
| Total Deal Value | $532M | $819M | $1.1B |
| Royalty Rate | 6.8% | — | 15.2% |
Comparable Deals
No territory-specific comparable deals. Use the calculator for full analysis.
See All Comparable Deals
View 0 comparable Oncology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 2 Oncology deals in US Only territory?
How does US Only territory affect Oncology deal value?
What royalty rates are typical for Phase 2 Oncology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$35M upfront
Oncology · Preclinical · US Only
$70M upfront
Oncology · Phase 1 · US Only
$338M upfront
Oncology · Phase 3 · US Only
$521M upfront
Oncology · Approved · US Only
$156M upfront
Neurology/CNS · Phase 2 · US Only
$299M upfront
Immunology · Phase 2 · US Only
$371M upfront
Metabolic/Obesity · Phase 2 · US Only
$235M upfront
Oncology · Phase 2 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Oncology Phase 2 Deal Benchmarks — US Only (2026). Retrieved from https://solidus.ambrosiaventures.co/data/oncology-phase-2-deals-us
<a href="https://solidus.ambrosiaventures.co/data/oncology-phase-2-deals-us">Oncology Phase 2 Deal Benchmarks — US Only (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=oncology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.